Dogwood Therapeutics
DWTX
16 hedge funds and large institutions have $6.17M invested in Dogwood Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
106% more capital inflows, than outflows
Capital inflows: $652K | Capital outflows: $317K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
0.55% more ownership
Funds ownership: 10.84% → 11.39% (+0.55%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$566K |
| 2 |
BlackRock
New York
|
+$47.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.7K |
| 5 |
Morgan Stanley
New York
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$244K |
| 2 |
Goldman Sachs
New York
|
-$30.8K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$24.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.65K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$8.24K |
DWTX Hedge Fund Activity: Q2 2026 in Review
16 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q2 2026, worth a combined $6.17M — down 19% from $7.64M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DWTX positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $566K. The largest seller was Armistice Capital, cutting an estimated $244K.
- 16 institutional investors held Dogwood Therapeutics (DWTX) as of Q2 2026, up from 14 in Q1 2026.
- Funds reported $6.17M of Dogwood Therapeutics stock for Q2 2026, down 19% quarter-over-quarter.
- 5 funds opened new Dogwood Therapeutics positions in Q2 2026 and 3 closed out, a net change of +2 holders.
- The largest Dogwood Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $566K added.
- The largest Dogwood Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $244K sold.
Based on aggregated 13F filings for Q2 2026.